MALVERN, PA--(Marketwire - March 8, 2010) - Auxilium Pharmaceuticals, Inc. ( NASDAQ : AUXL ), a specialty biopharmaceutical company, today announced that XIAFLEXT (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, is now available by prescription in the United States for the treatment of adult Dupuytren's contracture patients with a palpable cord.
[News Source]
[News Source]
Blogosphere: TechnoratiFeedsterBloglines
Bookmark: Del.icio.usSpurlFurlSimpyBlinkDigg


